China Approvals Rise But Conditional-To-Full Conversion Slips

Oncology Still Top For Drugs, Biologics

 
• By Xu Hu
  
Annual review
China's Central for Drug Evaluation recently published the annual report of drug review over the past year in 2024. (Shutterstock)

More from China

More from Pink Sheet